Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

Peter Seubert, Carmen Vigo-Pelfrey, Fred Esch, Michael Lee, Harry Dovey, Dave Davis, Sukanto Sinha, Michael Schiossmacher, Justine Whaley, Cathy Swindlehurst, Robert McCormack, Robert Wolfert, Dennis Selkoe, Ivan Lieberburg, Dale Schenk

Research output: Contribution to journalArticlepeer-review

1525 Scopus citations


CEREBRAL deposition of the β-amyloid peptide (Aβ) is an invariant feature of Alzheimer's disease. Since the original isola-tion and characterization of αβ (ref. 1) and the subsequent cloning of its precursor protein2-5, no direct evidence for the actual production of discrete Aβ has been reported6-11. Here we investigate whether Aβ is present in human biological fluids using antibodies specific for an epitope within Aβ that spans the site of normal constitutive cleavage 12,13. These antibodies were used to construct a sandwich type enzyme-linked immunosorbent assay that detects Aβ in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced Aβ and a novel Aβ fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that Aβ is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of Aβ.

Original languageEnglish (US)
Pages (from-to)325-327
Number of pages3
Issue number6393
StatePublished - 1992
Externally publishedYes


Dive into the research topics of 'Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids'. Together they form a unique fingerprint.

Cite this